Read the latest press releases for 4D pharma plc.

Click on a news title to read full details. For Regulatory News Service (RNS) announcements please click here.

Clinical
4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update
4 Jun 2021, 07:00
4D pharma completes target enrollment of 30 patients for Part A of its Phase I/II clinical trial of…
Clinical
4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome
24 May 2021, 07:00
New data demonstrating clinical activity of Live Biotherapeutic Blautix in both IBS-C and IBS-D was…
Presentations
4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021
17 May 2021, 07:00
4D pharma to Present Additional Data from its completed Phase II Study of Blautix for the Treatment…
4D pharma collaborates with Parkinson’s UK to establish Patient Advisory Board
19 Apr 2021, 07:00
4D pharma announces a collaboration with Parkinson’s UK, a non-profit organization focused on…
4D pharma to Participate in Jefferies Microbiome-Based Therapeutics Summit
15 Apr 2021, 07:00
4D pharma CEO, Duncan Peyton, and CSO, Alex Stevenson, will participate in a fireside chat at the…
4D pharma Announces Instructions for Converting AIM Listed Ordinary Shares into Nasdaq Listed ADSs
7 Apr 2021, 07:00
This announcement is intended to guide holders of Ordinary Shares, which are admitted to trading on…
Final Results for the year ended 31 December 2020
1 Apr 2021, 07:00
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live…
Completion of Merger with Longevity Acquisition Corporation and admission of American Depositary Shares to trading on NASDAQ
22 Mar 2021, 07:00
4D pharma's business combination with Longevity Acquisition Corporation has now become effective,…
4D pharma and Longevity receive shareholder approval to complete business combination
18 Mar 2021, 13:30
4D pharma and Longevity Acquisition Corporation receive shareholder approval to complete business…
4D Pharma Announces Private Placement
17 Mar 2021, 13:00
Company expects to complete merger with Longevity Acquisition Corporation and its American…
4D pharma to Present at Upcoming Investor Conferences in March
3 Mar 2021, 07:00
4D pharma management will present and meet with investors at three upcoming investor conferences…
4D pharma Appoints Paul Maier to the Board as Non-Executive Director
1 Mar 2021, 07:00
4D pharma announces the appointment of Paul Maier as Non-Executive Director of the Board. Mr Maier…
4D pharma Appoints John Beck as Chief Financial Officer
1 Mar 2021, 07:00
4D pharma announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the…
4D pharma Announces U.S. SEC Declares Registration Statement Effective with Respect to the Issuance of 4D Pharma American Depositary Shares on NASDAQ
26 Feb 2021, 07:00
4D pharma to list ADSs on NASDAQ in conjunction with the merger agreement between 4D pharma and…
4D pharma to Participate in Cantor Fitzgerald Microbiome Leaders Panel
16 Feb 2021, 07:00
Duncan Peyton, Chief Executive Officer of 4D pharma, will participate in Cantor Fitzgerald's virtual…

BACK TO TOP